




RealRate

PHARMACEUTICAL 2023

Dyne Therapeutics Inc
Rank 165 of 471



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Dyne Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Dyne Therapeutics Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 99% points. The greatest weakness of Dyne Therapeutics Inc is the variable Research and Development, reducing the Economic Capital Ratio by 25% points.

The company's Economic Capital Ratio, given in the ranking table, is 310%, being 66% points above the market average of 245%.

Input Variable	Value in 1000 USD
Assets, Current	265,594
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	28,088
Liabilities, Non-Current	25,873
Other Assets	34,786
Other Compr. Net Income	-302
Other Expenses	0
Other Liabilities	0
Other Net Income	2,863
Other Revenues	0
Property and Equipment	5,945
Research and Development	142,760
Selling, General and Administrative Expense	28,202

Output Variable	Value in 1000 USD
Assets	306,325
Liabilities	53,961
Expenses	170,962
Revenues	0
Stockholders Equity	252,364
Net Income	-168,099
Comprehensive Net Income	-168,250
BaseVar	267,206
ECR before Limited Liability	212%
Economic Capital Ratio	310%